Blurbs

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY) and Oric Pharmaceuticals (ORIC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DENTSPLY SIRONA (XRAYResearch Report) and Oric Pharmaceuticals (ORICResearch Report) with bullish sentiments.

DENTSPLY SIRONA (XRAY)

Barrington analyst Michael Petusky maintained a Buy rating on DENTSPLY SIRONA today and set a price target of $53.00. The company’s shares closed last Tuesday at $42.20, close to its 52-week low of $41.16.

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 9.2% and a 52.9% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, ATI Physical Therapy, and US Physical Therapy.

Currently, the analyst consensus on DENTSPLY SIRONA is a Moderate Buy with an average price target of $59.00, a 40.4% upside from current levels. In a report issued on April 5, Evercore ISI also maintained a Buy rating on the stock with a $65.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Oric Pharmaceuticals (ORIC)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Oric Pharmaceuticals yesterday and set a price target of $17.00. The company’s shares closed last Tuesday at $3.86, close to its 52-week low of $3.75.

According to TipRanks.com, Rama has 0 stars on 0-5 stars ranking scale with an average return of -3.1% and a 39.4% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Springworks Therapeutics.

Oric Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.50, which is a 220.5% upside from current levels. In a report issued on April 4, Citigroup also upgraded the stock to Buy with a $10.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on XRAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos